Search

Displaying results 4471 - 4480 of 4539 in total
  1. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).

  2. Drug

    Fish oil

    go.drugbank.com/drugs/DB13961
    ApprovedInvestigationalNutraceutical

    Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016. It is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient,...

  3. Drug

    Foretinib

    go.drugbank.com/drugs/DB12307
    Investigational

    Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound desig...

  4. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.

  5. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  6. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angio...

  7. Drug

    FK352B

    go.drugbank.com/drugs/DB06484
    Experimental

    FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.

  8. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    Poorly differentiated, highly invasive carcinomas are characterized by over-expression of N-cadherin (as opposed to E-cadherin).

  9. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vita...

  10. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represent...